UNC School of Medicine news release
T-cells are the immune system’s frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial, researchers have demonstrated that new vaccines can significantly boost T cells targeting the most vulnerable, conserved regions of HIV — areas considered key to effective immune control. This pivotal finding not only advances our understanding of HIV immunology but also offers hope that these vaccines could contribute to novel, curative approaches against HIV.
Led by a team of international researchers, the study is the first to test these HIV vaccines in people living with HIV who are receiving antiretroviral therapy.
Read the full news release here.
Source : UNC School of Medicine
Related HIV and Co-Infections News
-
BEEHIVE collaboration, SHCS: The genetic architecture of HIV-1 virulence
-
Johns Hopkins University: Study explains why HIV sometimes persists in blood post-treatment
-
The Conversation: HIV enters the brain and doesn’t leave – paradoxically, drugs intended to reduce brain inflammation increase virus levels
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.